Join to view full profile
750 Washington StBox 80Boston, MA 02111
Phone+1 617-636-0619
Dr. Surks is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Tufts Medical CenterFellowship, Cardiovascular Disease, 1994 - 1996- Tufts Medical CenterResidency, Internal Medicine, 1989 - 1992
Albert Einstein College of MedicineClass of 1989
Certifications & Licensure
NJ State Medical License 2012 - 2026
Publications & Presentations
PubMed
- 11 citationsFirst-in-human study with SAR445088: A novel selective classical complement pathway inhibitor.Timothy Chow, Pirouz Shamszad, Christopher Vinnard, Esther Yoon, Julia Belinski
Clinical and Translational Science. 2023-04-01 - 100 citationsHeart Failure With Preserved Ejection Fraction Expert Panel Report: Current Controversies and Implications for Clinical TrialsKishan S. Parikh, Kavita Sharma, Mona Fiuzat, Howard K. Surks, Jyothis T. George
JACC. Heart Failure. 2018-08-01 - 16 citationsSafety of Insulin Lispro and a Biosimilar Insulin Lispro When Administered Through an Insulin Pump.James Thrasher, Howard Surks, Irene Nowotny, Suzanne Pierre, Baerbel Rotthaeuser
Journal of Diabetes Science and Technology. 2018-01-23
Journal Articles
- Heart Failure with Preserved Ejection Fraction Expert Panel ReportKishan S Parikh, Howard K Surks, Sanjiv J Shah, Marvin A Konstam, Margaret M Redfield, Robert M Califf, Kavita Sharma, Narimon Honarpour, Gregory D Lewis, Scott D Solo..., ScienceDirect
Press Mentions
Immune Regulation Makes Peter Greenleaf Chairman and Assembles a Quintet of New Execs; Bob Coughlin Moves on from MassBio to JLLDecember 18th, 2020- Cardurion Pharmaceuticals Presents Positive Clinical Results from CARDINAL‑HF Phase 2a Clinical Trial of PDE9 Inhibitor in Patients with Heart FailureMay 14th, 2024
Grant Support
- Myosin Phosphatase Regulation In Vascular Smooth MuscleNational Heart, Lung, And Blood Institute2004–2008
- CGMP Dependent Protein Kinase In Vascular BiologyNational Heart, Lung, And Blood Institute1999–2003
- Cbmp Gated Channels In Cardiovascular PhysiologyNational Heart, Lung, And Blood Institute1995–1998
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
